Thursday, December 07, 2017

US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses - Full Article

SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses. Ulcers are common in the majority of horses that are subject to stress. Examples of horses under stress include race horses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse. In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%. Historically, ulcers have been known to negatively affect feeding habits and performance on the track.

A study, utilizing US Compounding’s unique drug formulation, was conducted in approximately 50 race horses. Gastric endoscopy was performed at day 0 and any time between days 14 and 21. Drug was administered after the first endoscopy as a paste given orally for 30 days. Endoscopic improvement was seen as early as 14 days. In greater than 95% of the horses the ulcers were shown to be clinically healed, as confirmed by endoscopy, with a reduction in gastric ulcer recovery times. A patent application covering this unique compounded product has been filed by the Company. In addition, a manuscript is in preparation...

Read more here

No comments: